The urea-based PSMA ligands NG001, labeled with 212Pb, and CA012 and L2, labeled with the surrogate 203Pb, show high tumor uptake (8–25%ID/g) 1–2 h post-injection in mice bearing PSMA-positive tumors, which is comparable with clinically used 177Lu-PSMA-617 [91,92,94,130,148]. Here, FOLH1 is linked to neoplasm.